HALOZYME THERAPEUTICS, INC. (HALO) Return on equity 2017–2025
HALOZYME THERAPEUTICS, INC. (HALO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
649.2%FY2025 · since FY2017: 30.2% → 649.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 649.2% | +527.1 pp |
| FY2024 | 122.1% | -213.9 pp |
| FY2023 | 336.0% | +217.0 pp |
| FY2022 | 119.0% | -85.4 pp |
| FY2021 | 204.5% | +119.0 pp |
| FY2020 | 85.5% | +164.2 pp |
| FY2019 | -78.7% | -46.4 pp |
| FY2018 | -32.3% | -62.5 pp |
| FY2017 | 30.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice